NanoViricides Common Stock Total Equity from 2010 to 2026
| NNVC Stock | USD 0.88 0.03 3.53% |
Common Stock Total Equity | First Reported 2006-06-30 | Previous Quarter 11.5 K | Current Value 11.5 K | Quarterly Volatility 46.8 K |
Check NanoViricides financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NanoViricides' main balance sheet or income statement drivers, such as Interest Expense of 179.9 M, Other Operating Expenses of 7.3 M or Research Development of 4.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.96 or PTB Ratio of 2.94. NanoViricides financial statements analysis is a perfect complement when working with NanoViricides Valuation or Volatility modules.
NanoViricides | Common Stock Total Equity | Build AI portfolio with NanoViricides Stock |
Analyzing NanoViricides's Common Stock Total Equity over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Common Stock Total Equity has evolved provides context for assessing NanoViricides's current valuation and future prospects.
Latest NanoViricides' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of NanoViricides over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. NanoViricides' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NanoViricides' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
NanoViricides Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 45,233 | |
| Geometric Mean | 29,253 | |
| Coefficient Of Variation | 90.74 | |
| Mean Deviation | 32,352 | |
| Median | 47,026 | |
| Standard Deviation | 41,045 | |
| Sample Variance | 1.7B | |
| Range | 146.6K | |
| R-Value | (0.80) | |
| Mean Square Error | 646.6M | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (6,503) | |
| Total Sum of Squares | 27B |
NanoViricides Common Stock Total Equity History
About NanoViricides Financial Statements
NanoViricides stakeholders use historical fundamental indicators, such as NanoViricides' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although NanoViricides investors may analyze each financial statement separately, they are all interrelated. For example, changes in NanoViricides' assets and liabilities are reflected in the revenues and expenses on NanoViricides' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NanoViricides. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 10.4 K | 9.8 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:Check out the analysis of NanoViricides Correlation against competitors. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Biotechnology sector continue expanding? Could NanoViricides diversify its offerings? Factors like these will boost the valuation of NanoViricides. Anticipated expansion of NanoViricides directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NanoViricides data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding NanoViricides requires distinguishing between market price and book value, where the latter reflects NanoViricides's accounting equity. The concept of intrinsic value - what NanoViricides' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push NanoViricides' price substantially above or below its fundamental value.
It's important to distinguish between NanoViricides' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NanoViricides should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NanoViricides' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.